Relationship Between Estimated Glycosylated Hemoglobin Using Flash Glucose Monitoring and Actual Measured Glycosylated Hemoglobin in a Chinese Population

Yun Hu, Yun Shen, Rengna Yan, Fengfei Li, Bo Ding, Huiying Wang, Xiaofei Su, Jianhua Ma, Yun Hu, Yun Shen, Rengna Yan, Fengfei Li, Bo Ding, Huiying Wang, Xiaofei Su, Jianhua Ma

Abstract

Introduction: The aim of this study was to investigate the relationship between actual measured glycated hemoglobin (HbA1c) and estimated glycated hemoglobin (EA1c) in the flash glucose monitoring (FGM) system in Chinese patients with type 2 diabetes.

Methods: This study was conducted in Nanjing First Hospital. Each patient used FGM twice in a 3-month period (during the first 14 days immediately after baseline and during a second 14-day period from days 76 to 90 after baseline). HbA1c measurements were made using a high-performance liquid chromatography assay before the start of the first FGM period (baseline) and at the end of the second FGM period.

Results: A total of 74 patients (35 men; mean age ± standard deviation [SD] 67.6 ± 5.2 years) were enrolled in the study. The mean (± SD) duration of diabetes was 11.9 ± 7.8 months. The first and second HbA1c measurements were both higher than the EA1c (both p < 0.001). Mean glucose (MG) gradually decreased over time and was the lowest on day 14. Linear regression showed that only HbA1c at baseline affected the gap between HbA1c and EA1c (β = 0.319, p = 0.01) when the educational level, age, gender, duration of diabetes, body mass index, HbA1c at baseline, and number of scans daily were included as independent variables. The best model for calculating EA1c was EA1c% = MG mmol/L × 0.669 - 0.213 × 8th MG + 3.351 when MG > 9.7 mmol/L, and EA1c % = (MG mmol/L + 2.590)/1.590 when MG ≤ 9.7 mmol/L. The correlation coefficient for EA1c and HbA1c in this model (model 7) is higher than that reported the original model in the FGM system 1 (0.955 vs. 0.822, respectively; p < 0.001).

Conclusions: The EA1c used by FreeStyle Libre™ is lower than the actual measured HbA1c. Improvement in the glucose levels during FGM in these patients may contribute to the lowering of EA1c.

Trial registration: The study is registered with ClinicalTrials.gov, number NCT03785301.

Keywords: Estimated glycated hemoglobin; Flash glucose monitoring; Glycated hemoglobin.

Figures

Fig. 1
Fig. 1
Daily mean glucose of the patients during 14 days of flash glucose monitoring (FGM). Values are pooled data from two 14-day FGM monitoring periods. Asterisk(s) indicates a signficance difference in mean glucose (MG) as compared to MG on third day of 14-day FGM (*p < 0.05; **p < 0.01)
Fig. 2
Fig. 2
Relationship between glycated hemoglobin (HbA1c) and the gap between actual measured HbA1c (A1c) and estimated A1c (EA1c) during FGM. A total of 148 HbA1c measurements and the corresponding EA1c in the FGM system were included in linear regression

References

    1. Al-Agha AE, Kafi SE, Zain Aldeen AM, Khadwardi RH. Flash glucose monitoring system may benefit children and adolescents with type 1 diabetes during fasting at Ramadan. Saudi Med J. 2017;38(4):366–371.
    1. Dunn TC, Xu Y, Hayter G, Ajjan RA. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests. Diabetes Res Clin Pract. 2018;137:37–46.
    1. Jangam S, Dunn T, Xu Y, Hayter G, Ajjan RA. Flash glucose monitoring improves glycemia in higher risk patients: a longitudinal, observational study under real-life settings. BMJ Open Diabetes Res Care. 2019;7(1):e000611.
    1. Hellmund R, Weitgasser R, Blissett D. Cost calculation for a flash glucose monitoring system for adults with Type 2 diabetes mellitus using intensive insulin: a UK perspective. Eur Endocrinol. 2018;14(2):86–92.
    1. American Diabetes Association 6. Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S61–S70.
    1. Jovanovic L, Savas H, Mehta M, Trujillo A, Pettitt DJ. Frequent monitoring of A1C during pregnancy as a treatment tool to guide therapy. Diabetes Care. 2011;34(1):53–54.
    1. Forbes A, Murrells T, Mulnier H, Sinclair AJ. Mean HbA 1c, HbA 1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(6):476–486.
    1. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med. 1976;295(8):417–420.
    1. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25(2):275–278.
    1. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007;50(11):2239–2244.
    1. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473–1478.
    1. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated Type 2 diabetes: a multicenter open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55–73.
    1. Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care. 2019;42(7):1178–1184.
    1. Dover AR, Stimson RH, Zammitt NN, Gibb FW. Flash glucose monitoring improves outcomes in a type 1 diabetes clinic. J Diabetes Sci Technol. 2017;11(2):442–443.
    1. McKnight JA, Gibb FW. Flash glucose monitoring is associated with improved glycaemic control but use is largely limited to more affluent people in a UK diabetes centre. Diabetes Med. 2017;34(5):732.
    1. Kumagai R, Muramatsu A, Fujii M, et al. Comparison of glucose monitoring between Freestyle Libre Pro and iP ro2 in patients with diabetes mellitus. J Diabetes Investig. 2019;10(3):851–856.
    1. Leelarathna L, Wilmot EG. Flash forward: a review of flash glucose monitoring. Diabet Med. 2018;35(4):472–482.
    1. Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17(11):787–794.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다